Cost-effectiveness results
| Cohort age (years) | Technologies | Total cost | Total LYG | Total QALYs | Inc costs (95% CI) | Inc LYG (95% CI) | Inc QALYs (95% CI) | ICER | Inc NMB (95% CI) |
| 11 | Surveillance | £8548 | 56.62 | 23.24 | £2185 (£430 to £4144) | 1.25 (0.303 to 1.859) | 0.29 (0.066 to 0.426) | £7657 | £3522 (£−2747 to £7652) |
| No surveillance | £6363 | 55.36 | 22.95 | ||||||
| 18 | Surveillance | £9061 | 54.22 | 22.27 | £1692 (£−312 to £3810) | 1.45 (0.339 to 2.184) | 0.34 (0.078 to 0.516) | £4950 | £5144 (£−2022 to £10 189) |
| No surveillance | £7280 | 52.81 | 21.94 | ||||||
| 40 | Surveillance | £11 892 | 37.79 | 17.80 | -£965 (−£4202 to £2652) | 1.52 (0.304 to 2.258) | 0.58 (0.115 to 0.869) | Dominant | £12 655 (£−709 to £21 134) |
| No surveillance | £12 857 | 36.27 | 17.21 | ||||||
| 60 | Surveillance | £8357 | 21.40 | 12.08 | £623 (−£698 to £1968) | 0.30 (0.091 to 0.450) | 0.16 (0.046 to 0.236) | £3982 | £2507 (£−934 to £5233) |
| No surveillance | £7734 | 21.10 | 11.92 |
ICER, incremental cost-effectiveness ratio; Inc, incremental; LYG, life years gained; NMB, net monetary benefit; QALY, quality-adjusted life-year.